LYN抗体—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using P08490(LYN Antibody) at dilution 1/20. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P08490(LYN Antibody) at dilution 1/20. (Original magnification: ×200)    

  
  

The LYN antibody targets LYN, a non-receptor tyrosine kinase belonging to the SRC family. Primarily expressed in hematopoietic cells, particularly B cells and myeloid cells, LYN plays dual roles in intracellular signaling. It regulates key pathways, including B-cell receptor (BCR) signaling, cytokine receptor activation, and integrin-mediated responses. LYN activates downstream effectors like SYK and PI3K but also exerts inhibitory effects by phosphorylating immunoreceptor tyrosine-based inhibitory motifs (ITIMs) on receptors such as CD22 and FcγRIIB. This duality contributes to its involvement in both pro-survival and anti-proliferative signals.

Dysregulated LYN activity is implicated in hematologic malignancies (e.g., chronic lymphocytic leukemia, acute myeloid leukemia) and autoimmune disorders (e.g., systemic lupus erythematosus). Overexpression or mutations in LYN can lead to constitutive signaling, promoting cell survival and resistance to apoptosis. Conversely, loss of LYN function may disrupt immune tolerance.

LYN antibodies are essential tools for studying its expression, phosphorylation status, and interactions in disease models. They aid in elucidating LYN's role in oncogenesis and immune dysregulation, as well as evaluating therapeutic strategies targeting LYN, such as small-molecule inhibitors (e.g., dasatinib) or monoclonal antibodies in preclinical and clinical development. Research continues to explore LYN's context-dependent signaling mechanisms and its potential as a biomarker or therapeutic target.